ArticleCancer immunology, immunotherapy : CII2010
Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.
Article in Cancer immunology, immunotherapy : CII, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05163080 (Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma), which is not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Who cites it
35 citing papers in PubMed, 65 citations in OpenAlex.
- Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.Cancer immunology, immunotherapy : CII · 2016Trial
- Emerging frontiers in glioma therapy: the evolving role of glioma vaccines.Frontiers in immunology · 2026Review
- Disrupting PDGFRA-driven immune evasion in glioma: vaccine-based strategies on the horizon.Frontiers in oncology · 2026Review
- Immunologic specificity in glioblastoma: Antigen discovery and translational implications.Neuro-oncology advances · 2025Review
- Eliciting antitumor immunity via therapeutic cancer vaccines.Cellular & molecular immunology · 2025Review
- Recent developments in peptide vaccines against Glioblastoma, a review and update.Molecular brain · 2025Review
- Review
- Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Peptide-based vaccine for cancer therapies.Frontiers in immunology · 2023Review
- From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy.Frontiers in chemistry · 2022Review
- AIM™ platform: A new immunotherapy approach for viral diseases.Frontiers in medicine · 2022Article
- Article
- Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma.Science translational medicine · 2021Article
- Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.Cancers · 2021Article
- Peptide-based therapeutic cancer vaccine: Current trends in clinical application.Cell proliferation · 2021Review
- Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.Frontiers in immunology · 2021Review
- Exploring the role of survivin in neuroendocrine neoplasms.Oncotarget · 2020Article
- Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor GrowthClinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma.Frontiers in oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Survivin is a tumor-associated antigen with significant potential as a cancer vaccine target. We have identified a survivin peptide mimic containing human MHC class I epitopes and a potential class II ligand that induces a potent antitumor response in C57BL/6 mice with GL261 cerebral gliomas. This peptide is able to elicit both CD8+ CTL and T helper cell responses in C57BL/6 mice. The corresponding region of the human survivin molecule represented by peptide SVN53-67 is 100% homologous to the murine protein, but SVN53-67 is weakly immunogenic in man. We evaluated several amino acid substitutions in putative human MHC I anchor positions in SVN53-67 to identify potential peptide mimics that could provide an enhanced antitumor immune response against human glioma and primary central nervous system lymphoma (PCNSL) cells in culture. We evaluated survivin peptides with predicted binding to human HLA-A*0201 antigen using peptide-loaded dendritic cells from PBMC of patients with these malignancies. One alteration (M57) led to binding to HLA-A*0201 with significantly higher affinity. We compared the ability of autologous dendritic cells loaded with SVN53-67 peptide and SVN53-67/M57 in CTL assays against allomatched and autologous, survivin-expressing, human malignant glioma and PCNSL cells. Both SVN53-67 and SVN53-67/M57 produced CTL-mediated killing of malignant target cells; however, SVN53-67/M57 was significantly more effective than SVN53-67. Thus, SVN53-67/M57 may act as a peptide mimic to induce an enhanced antitumor CTL response in tumor patients. The use of SVN53-67/M57 as a cancer vaccine might have application for cancer vaccine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.